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The term stable coronary artery disease encompasses a range of
patient categories, including patients with classic angina
pectoris and those with previous obstructive acute or stable
coronary artery disease (CAD) who have been successfully
treated. Although stable CAD per deﬁnition can be
considered a low-risk group compared with patients with
acute coronary syndromes (ACS), it is associated with a
substantial long-term risk of adverse events (2). Within
the overall group of patients with stable CAD, there is
considerable variation in risk, and the risk may vary over
time on the individual level. Serial prognostic assessment
could therefore be of considerable importance as a tool to
identify patients who might beneﬁt from appropriate and
timely diagnostic evaluation and therapeutic intervention.
Equally important, prognostic assessment may be used to
identify low-risk patients who may safely be treated con-
servatively, thus avoiding unnecessary invasive investigations
and therapeutic procedures.See page 345Until recently, measurement of cardiac troponin levels
has been almost exclusively performed to diagnose acute
ischemic injury in patients with suspected acute myocardial
infarction (MI). In parallel with the gradual improvement
in analytical performance of assays, progressively lower
circulating concentrations of cardiac troponins can be
detected with acceptable precision, paving the way forublished in the Journal of the American College of Cardiology reﬂect the
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ospital.accurate quantiﬁcation of chronic circulating concentrations
in low-risk groups (3). Even within this low-level range,
cardiac troponin levels measured by a new generation of
sensitive assays have been shown to be robustly associated
with the risk of cardiovascular death and heart failure (4–6).
Somewhat unexpectedly, the association with MI is weaker
and attenuated after adjustment for conventional risk
markers (4).
In this issue of the Journal, White et al. (7) report data
from the biomarker substudy of the LIPID (Long-Term
Intervention with Pravastatin in Ischaemic Disease) trial,
performed in the 1990s (8). The main trial tested the effect
of pravastatin 40 mg versus placebo in a large cohort of
patients with a history of ACS and was stopped prema-
turely because of a beneﬁcial effect of the intervention.
The current report evaluated the association between
baseline cardiac troponin I concentrations and their
change during the ﬁrst year of follow-up and the risk of the
composite primary endpoint of death due to cardiovascular
causes or nonfatal MI. Moreover, the study examined the
potential interaction between cardiac troponin I levels and
the effect of the intervention. The results of this well-
conducted study conﬁrm and extend previous results,
suggesting that the measurement of cardiac troponin levels
using contemporary sensitive methods can reﬁne risk
prediction among patients with stable CAD. Moreover,
the study shed light on some of the yet unanswered
questions related to the use of cardiac troponins in this
patient group. First, conﬁrming data from the PEACE
(Prevention of Events With Angiotensin Converting
Enzyme Inhibition) study (4,9), cardiac troponin I, after
adjustment for a comprehensive risk marker model, was-
robustly associated with the incidence of cardiovascular
death and heart failure, whereas the association with stroke
and nonfatal MI, although nominally statistically signiﬁ-
cant, was weaker. For the composite primary endpoint of
cardiovascular death or nonfatal MI, cardiac troponin I
added to the baseline model resulted in a modest but
signiﬁcant net reclassiﬁcation improvement.
Whether change in cardiac troponins measured with
highly sensitive assays provides additional prognostic infor-
mation to that obtained from baseline measurements alone
has previously been assessed in elderly individuals from the
general population (6) and patients with chronic systolic
heart failure (10). Extending these results, the LIPID
investigators demonstrated that in patients with stable
CAD, the shift from a lower concentration to higher
concentration category is associated with increased risk,
independently of baseline levels and other risk markers.
Moreover, measurements performed at baseline and after 1
year provided independent prognostic information, sug-
gesting that serial monitoring of cardiac troponin levels
reﬂects dynamic changes in cardiovascular risk.
Do these ﬁndings suggest that cardiac troponin
measurements should be recommended in the routine
follow-up of this large patient group? Although risk
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356stratiﬁcation and knowledge about change in risk may
suggest to the clinician that patients with high and in-
creasing risk should be monitored more closely and poten-
tially managed more aggressively than patients with low or
decreasing risk, it offers no speciﬁc guidance to what therapy
will beneﬁt patients. In other words, although it may seem
reasonable to refer patients with stable CAD and high and/
or increasing troponin concentrations to noninvasive or
invasive diagnostic tests and to consider intensifying therapy,
it is still unknown whether this strategy will lead to
improved patient outcome. Conversely, we lack data de-
monstrating that it would be safe to withdraw conventionally
accepted secondary prevention measures in patients with
stable CAD and low and/or decreasing troponin levels.
Use of cardiac troponins as a guide to therapy in a person-
alized medicine strategy has successfully been demonstrated
in ACS, when it was convincingly shown that patients
with chest pain with elevated cardiac troponin levels on
admission beneﬁted from intensiﬁed medical therapy (11)
and from an early invasive versus a conservative strategy
(12). Conversely, patients with troponin levels within the
normal range did not seem to beneﬁt from such intensi-
ﬁcation of therapy (11,12). These observations have contrib-
uted to the routine use of cardiac troponin measurements in
patients presenting to the hospital with acute chest pain and
suspected acute MI (13), and the use of cardiac troponin
levels to guide treatment decisions in ACS represents a
preeminent example of a successful personalized medicine
strategy within the ﬁeld of cardiovascular medicine.
Statin therapy is a cornerstone in the management of
patients with stable CAD. The hypothesis that risk strati-
ﬁcation based on cardiac troponin concentrations can be
used to predict the effect of statins, as tested in the LIPID
substudy, is interesting, although it can be argued that in
the stable CAD setting, chronic elevation of cardiac
troponins may preferentially reﬂect other pathophysiological
processes than those primarily affected by the lipid-
lowering and pleiotropic effects of statin therapy. In the
LIPID trial, treatment with pravastatin was associated with
a slight but statistically signiﬁcant reduction of cardiac
troponin I at 1 year. However, the relative treatment effect
on clinical outcomes was similar across different categories
of cardiac troponin I, and no formal interaction between
cardiac troponin I levels and the effect of pravastatin was
evident, suggesting no clinically important utility of these
biomarkers as a tool for selection of patients who will
beneﬁt from statin therapy. The authors observed that
higher baseline cardiac troponin levels were associated with
a larger absolute beneﬁt from pravastatin, and thus, the
number needed to treat was less in patients with high than
in those with low baseline levels. Given that higher
troponin I levels were associated with higher absolute risk
and the relative risk reduction was similar across troponin
categories, this observation is not surprising and just reﬂects
the inverse association between absolute risk reduction and
number needed to treat.A variety of potential causes of cardiac troponin eleva-
tion could account for the observed association with
cardiovascular risk. Thus, it is not clear that statin therapy
would be the optimal intervention to test the hypothesis that
troponins can be used in a personalized medicine strategy to
identify patients likely to beneﬁt from therapy. Recent
data suggest that mild, chronic elevation of cardiac tropo-
nins is more strongly associated with cardiac anatomy and
function than with the extent of CAD (5). Moreover, the
combination of left ventricular hypertrophy and elevated
cardiac troponins seems to identify a particularly malignant
phenotype (14). This suggests that interventions aimed at
reducing myocardial strain and reversing cardiomyocyte
hypertrophy may be more effective at reducing cardiac
troponin levels than statins, and it is conceivable that
cardiac troponins would be predictive of the effect of such
interventions. Still, retrospective data from the PEACE
study failed to show any interaction between cardiac troponin
T levels at baseline and the beneﬁt of the angiotensin-
converting enzyme inhibitor trandolapril in low-risk
patients with stable CAD (4). Thus, despite the important
ﬁnding of the LIPID study that serial troponin measurement
can reﬁne risk stratiﬁcation in stable CAD, the clinical beneﬁt
of the theoretically beautiful strategy of using cardiac tropo-
nins as a management criterion in this patient group remains
unproven. Prospectively and intelligently designed trials
testing interventions that both are pathophysiologically
linked to cardiac troponin production and are effective in
reducing risk associated with such pathophysiology in stable
CAD will be required to deﬁnitively answer the decisive
question of whether cardiac troponin measurements can
translate into improved patient management.
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